Apellis Pharmaceuticals, Inc. (NASDAQ:APLS - Free Report) - Analysts at Cantor Fitzgerald dropped their FY2025 earnings estimates for Apellis Pharmaceuticals in a report released on Thursday, May 8th. Cantor Fitzgerald analyst S. Seedhouse now anticipates that the company will earn ($2.38) per share for the year, down from their prior forecast of ($0.94). Cantor Fitzgerald currently has a "Overweight" rating and a $44.00 target price on the stock. The consensus estimate for Apellis Pharmaceuticals' current full-year earnings is ($1.70) per share.
A number of other analysts also recently issued reports on the stock. JPMorgan Chase & Co. increased their price target on shares of Apellis Pharmaceuticals from $50.00 to $54.00 and gave the stock an "overweight" rating in a report on Tuesday, March 4th. Wedbush lowered their price target on shares of Apellis Pharmaceuticals from $30.00 to $29.00 and set a "neutral" rating on the stock in a report on Monday, March 3rd. Needham & Company LLC lowered their price target on shares of Apellis Pharmaceuticals from $40.00 to $29.00 and set a "buy" rating on the stock in a report on Wednesday, May 7th. Mizuho dropped their target price on shares of Apellis Pharmaceuticals from $30.00 to $20.00 and set a "neutral" rating on the stock in a research report on Wednesday. Finally, Raymond James lowered shares of Apellis Pharmaceuticals from a "strong-buy" rating to an "outperform" rating and dropped their target price for the company from $75.00 to $52.00 in a research report on Friday, May 9th. Nine investment analysts have rated the stock with a hold rating, eleven have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and an average target price of $40.42.
Get Our Latest Stock Report on APLS
Apellis Pharmaceuticals Stock Performance
NASDAQ APLS traded up $1.06 during mid-day trading on Monday, reaching $17.42. 749,744 shares of the stock were exchanged, compared to its average volume of 2,229,723. The business's 50 day moving average is $20.48 and its 200-day moving average is $26.77. Apellis Pharmaceuticals has a 1 year low of $16.10 and a 1 year high of $43.99. The company has a market capitalization of $2.19 billion, a P/E ratio of -8.55 and a beta of 0.73. The company has a debt-to-equity ratio of 1.91, a quick ratio of 3.73 and a current ratio of 4.36.
Apellis Pharmaceuticals (NASDAQ:APLS - Get Free Report) last announced its quarterly earnings results on Wednesday, May 7th. The company reported ($0.74) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.36) by ($0.38). Apellis Pharmaceuticals had a negative return on equity of 103.11% and a negative net margin of 34.97%. The firm had revenue of $149.90 million for the quarter, compared to analysts' expectations of $197.61 million. During the same period last year, the company posted ($0.54) earnings per share. The business's quarterly revenue was down 3.2% on a year-over-year basis.
Institutional Inflows and Outflows
A number of institutional investors have recently added to or reduced their stakes in the company. EverSource Wealth Advisors LLC increased its stake in Apellis Pharmaceuticals by 2,707.1% in the 4th quarter. EverSource Wealth Advisors LLC now owns 786 shares of the company's stock valued at $25,000 after buying an additional 758 shares during the period. Signaturefd LLC increased its stake in Apellis Pharmaceuticals by 357.2% in the 4th quarter. Signaturefd LLC now owns 1,175 shares of the company's stock valued at $37,000 after buying an additional 918 shares during the period. Assetmark Inc. increased its stake in Apellis Pharmaceuticals by 3,938.7% in the 1st quarter. Assetmark Inc. now owns 1,252 shares of the company's stock valued at $27,000 after buying an additional 1,221 shares during the period. GF Fund Management CO. LTD. acquired a new position in Apellis Pharmaceuticals in the 4th quarter valued at $83,000. Finally, US Bancorp DE increased its stake in Apellis Pharmaceuticals by 70.0% in the 4th quarter. US Bancorp DE now owns 3,223 shares of the company's stock valued at $103,000 after buying an additional 1,327 shares during the period. Hedge funds and other institutional investors own 96.29% of the company's stock.
Insider Activity at Apellis Pharmaceuticals
In related news, General Counsel David O. Watson sold 5,569 shares of Apellis Pharmaceuticals stock in a transaction that occurred on Wednesday, March 5th. The shares were sold at an average price of $25.10, for a total value of $139,781.90. Following the completion of the transaction, the general counsel now owns 138,730 shares in the company, valued at approximately $3,482,123. The trade was a 3.86% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Company insiders own 6.50% of the company's stock.
Apellis Pharmaceuticals Company Profile
(
Get Free Report)
Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).
Featured Stories
Before you consider Apellis Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Apellis Pharmaceuticals wasn't on the list.
While Apellis Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
